

Brad S Kahl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7400633/publications.pdf>

Version: 2024-02-01

166
papers

10,469
citations

87723

38
h-index

34900

98
g-index

169
all docs

169
docs citations

169
times ranked

10059
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 541-554.	0.8	23
2	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. <i>Journal of Clinical Oncology</i> , 2023, 41, 336-342.	0.8	9
3	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	0.6	50
4	The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e335-e339.	0.2	19
5	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	2.5	3
6	COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 1723-1727.	0.6	1
7	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. <i>Blood Advances</i> , 2022, 6, 2035-2044.	2.5	12
8	Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up. <i>HemaSphere</i> , 2022, 6, e712.	1.2	21
9	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
10	Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. <i>Blood Advances</i> , 2022, 6, 4736-4739.	2.5	1
11	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2021, 137, 2634-2645.	0.6	111
12	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	0.8	60
13	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 3339-3350.	3.2	26
14	ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≥65y with untreated non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7572-TPS7572.	0.8	7
15	Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7546-7546.	0.8	2
16	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 790-800.	5.1	211
17	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	1.3	21
18	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	2.5	21
20	Zanubrutinib monotherapy for patients with treatment-naïve chronic lymphocytic leukemia and 17p deletion. <i>Haematologica</i> , 2021, 106, 2354-2363.	1.7	62
21	Dose Finding Study of Ibrutinib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood Advances</i> , 2021, , .	2.5	5
22	SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 396-396.	0.6	22
23	Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial. <i>Blood</i> , 2021, 138, 3575-3575.	0.6	2
24	Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. <i>Lancet Haematology</i> , 2021, 8, e891-e901.	2.2	15
25	Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. <i>Acta Haematologica</i> , 2020, 143, 40-50.	0.7	27
26	MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial. <i>Leukemia</i> , 2020, 34, 522-532.	3.3	26
27	Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	2.0	18
28	Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 861-870.	0.9	2
29	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	0.8	75
30	CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 3850-3852.	2.5	46
31	Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. <i>Lancet Haematology</i> , 2020, 7, e660-e670.	2.2	86
32	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. <i>Leukemia and Lymphoma</i> , 2020, 61, 2442-2447.	0.6	1
33	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2519-2529.	0.8	93
34	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020, 135, 2224-2234.	0.6	62
35	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	2.5	40
36	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. <i>Blood</i> , 2020, 136, 2308-2318.	0.6	133

#	ARTICLE	IF	CITATIONS
37	Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 663-672.	0.9	2
38	CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. Blood, 2020, 136, 27-28.	0.6	9
39	Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 35-37.	0.6	14
40	Outcomes of Patients with Relapsed Mantle Cell Lymphoma Treated with Venetoclax: A Multicenter Retrospective Analysis. Blood, 2020, 136, 4-6.	0.6	7
41	A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma. Blood, 2020, 136, 32-34.	0.6	2
42	Frontline CLL Options: An Embarrassment of Riches?. , 2020, 17, .		0
43	Recent Advances in Antibody-Drug Conjugates for Lymphoma. Oncology, 2020, 34, 522-534.	0.4	1
44	Picking a Partner: As in Life, it Matters for MYC. , 2020, 17, .		0
45	Are We Capable of Curing Follicular Lymphoma, But Just Afraid to Say It?. , 2020, 17, .		0
46	Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. Blood, 2020, 136, 15-16.	0.6	0
47	Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]. Blood, 2020, 136, 50-50.	0.6	0
48	Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma. Blood, 2020, 136, 24-25.	0.6	1
49	Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma. Blood, 2020, 136, 3-4.	0.6	4
50	Highlights in mantle cell lymphoma from the 2020 American Society of Clinical Oncology Annual Meeting: commentary. Clinical Advances in Hematology and Oncology, 2020, 18 Suppl 11, 14-17.	0.3	0
51	The role of autologous stem cell transplantation in patients with nodal peripheral Tâ€cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer, 2019, 125, 1507-1517.	2.0	106
52	Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. , 2019, 7, 70.		19
53	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of Clinical Oncology, 2019, 37, 1790-1799.	0.8	266
54	First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. Journal of Clinical Oncology, 2019, 37, 984-991.	0.8	183

#	ARTICLE	IF	CITATIONS
55	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , 2019, 133, 1762-1765.	0.6	35
56	An iatrogenic orphan?. <i>Blood</i> , 2019, 134, 1273-1274.	0.6	1
57	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3132-3135.	2.5	18
58	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolbenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 6986-6994.	3.2	77
59	Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 524-535.	1.2	27
60	Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas Into Effective New Therapies?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 65-67.	0.2	0
61	Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. <i>Haematologica</i> , 2019, 104, e211-e214.	1.7	122
62	Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study. <i>Blood</i> , 2019, 134, 5243-5243.	0.6	4
63	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	0.6	4
64	Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial. <i>Blood</i> , 2019, 134, 126-126.	0.6	12
65	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. <i>Blood</i> , 2019, 134, 349-349.	0.6	13
66	Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up. <i>Blood</i> , 2019, 134, 1538-1538.	0.6	20
67	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial. <i>Blood</i> , 2019, 134, 499-499.	0.6	23
68	Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolbenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 757-757.	0.6	7
69	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753.	0.6	9
70	Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2019, 134, 1535-1535.	0.6	7
71	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3483-3483.	0.6	1
72	Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2019, 134, 751-751.	0.6	18

#	ARTICLE	IF	CITATIONS
73	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019, 134, 1525-1525.	0.6	10
74	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 69-69.	0.6	9
75	Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7505-7505.	0.8	5
76	Can We Use MRD Status to Personalize Therapy in Mantle Cell Lymphoma?. , 2019, 16, .		0
77	Is It Time for Time-limited Therapy in Frontline CLL?. , 2019, 16, .		0
78	Keeping Your ESCHELONS Straight. , 2019, 16, .		0
79	Is Double-hit Diffuse Large B-cell Lymphoma More Common Than We Think?. , 2019, 16, .		0
80	RIP FCR?. , 2019, 16, .		1
81	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 5891-5891.	0.6	0
82	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas. <i>Blood</i> , 2019, 134, 1550-1550.	0.6	1
83	A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404. <i>Blood</i> , 2019, 134, 1541-1541.	0.6	0
84	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. <i>Blood</i> , 2018, 131, 2060-2064.	0.6	167
85	Targeting BCL-2 in Hematologic Malignancies. <i>Targeted Oncology</i> , 2018, 13, 257-267.	1.7	27
86	Indolent lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 1.	0.7	0
87	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018, 8, 27.	2.8	10
88	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.	2.0	47
89	VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e61-e67.	0.2	13
90	Duvelisib, a novel oral dual inhibitor of PI3K-Î±,Î³, is clinically active in advanced hematologic malignancies. <i>Blood</i> , 2018, 131, 877-887.	0.6	199

#	ARTICLE	IF	CITATIONS
91	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood, 2018, 132, 1013-1021.	0.6	90
92	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. Blood, 2018, 132, 145-145.	0.6	5
93	Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. Blood, 2018, 132, 929-929.	0.6	6
94	Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis. Blood, 2018, 132, 2927-2927.	0.6	2
95	The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imidazole Continuation (BIONIC) Study. Blood, 2018, 132, 1615-1615.	0.6	1
96	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. Blood, 2018, 132, 1702-1702.	0.6	6
97	A Phase I Study with an Expansion Cohort of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Research Group (E4412: Arms G-I). Blood, 2018, 132, 679-679.	0.6	13
98	Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. Blood, 2018, 132, 453-453.	0.6	1
99	Outcomes of Follicular Lymphoma Patients Treated with Frontline Bendamustine and Rituximab: Impact of Histologic Grade and Early Progression on Overall Survival. Blood, 2018, 132, 4146-4146.	0.6	8
100	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). Blood, 2018, 132, 623-623.	0.6	1
101	Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.. Journal of Clinical Oncology, 2018, 36, 10042-10042.	0.8	1
102	ILyAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy.. Journal of Clinical Oncology, 2018, 36, TPS7587-TPS7587.	0.8	0
103	Immune toxicity in post autologous transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade.. Journal of Clinical Oncology, 2018, 36, 7538-7538.	0.8	0
104	Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. Blood, 2018, 132, 2878-2878.	0.6	0
105	Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance. Blood, 2018, 132, 5277-5277.	0.6	0
106	Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Mantle Cell Lymphoma. Blood, 2018, 132, 1593-1593.	0.6	0
107	A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. Blood, 2018, 132, 4157-4157.	0.6	0
108	Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma. Clinical Advances in Hematology and Oncology, 2018, 16, 732-734.	0.3	3

#	ARTICLE	IF	CITATIONS
109	Recommendations for Clinical Trial Development in Follicular Lymphoma. Journal of the National Cancer Institute, 2017, 109, djw255.	3.0	23
110	Long-term safety experience with bendamustine for injection in a real-world setting. Expert Opinion on Drug Safety, 2017, 16, 647-650.	1.0	2
111	A prospective cohort study of patients with peripheral Tâ€cell lymphoma in the United States. Cancer, 2017, 123, 1174-1183.	2.0	51
112	Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. Journal of the National Cancer Institute, 2017, 109, djw249.	3.0	31
113	T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. Journal of the National Cancer Institute, 2017, 109, djw248.	3.0	28
114	Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. Journal of the National Cancer Institute, 2017, 109, djw263.	3.0	10
115	Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study. Haematologica, 2017, 102, e156-e159.	1.7	68
116	Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three openâ€label studies. British Journal of Haematology, 2017, 179, 430-438.	1.2	116
117	NR4A1 inhibition synergizes with ibrutinib in killing mantle cell lymphoma cells. Blood Cancer Journal, 2017, 7, 632.	2.8	3
118	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 675.	2.2	18
119	Follicular lymphoma: are we ready for a risk-adapted approach?. Hematology American Society of Hematology Education Program, 2017, 2017, 358-364.	0.9	14
120	Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma. Journal of Clinical Oncology, 2017, 35, 826-833.	0.8	596
121	Current Approaches to Mantle Cell Lymphoma: Diagnosis, Prognosis, and Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 512-525.	1.8	16
122	Personalized risk prediction for eventâ€free survival at 24 months in patients with diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2016, 91, 179-184.	2.0	41
123	Rituximab extended schedule or retreatment trial for low tumour burden nonâ€follicular indolent Bâ€cell nonâ€Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. British Journal of Haematology, 2016, 173, 867-875.	1.2	36
124	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
125	General Biomarker Recommendations for Lymphoma. Journal of the National Cancer Institute, 2016, 108, djw250.	3.0	2
126	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. Journal of the National Cancer Institute, 2016, 108, djw257.	3.0	56

#	ARTICLE	IF	CITATIONS
127	Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1543-1551.	2.0	42
128	Follicular lymphoma: evolving therapeutic strategies. <i>Blood</i> , 2016, 127, 2055-2063.	0.6	142
129	BV for HL: can the responses last?. <i>Blood</i> , 2016, 128, 1540-1541.	0.6	0
130	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 311-322.	13.9	1,532
131	Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 821-826.	3.2	26
132	Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update. <i>Leukemia and Lymphoma</i> , 2016, 57, 766-782.	0.6	70
133	Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study. <i>Blood</i> , 2016, 128, 149-149.	0.6	2
134	Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2016, 128, 2958-2958.	0.6	4
135	Long-Term Safety Experience with Bendamustine for Injection in a Real-World Setting. <i>Blood</i> , 2016, 128, 5591-5591.	0.6	0
136	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , 2015, 126, 739-745.	0.6	349
137	Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). <i>Journal of Clinical Oncology</i> , 2015, 33, 740-748.	0.8	36
138	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	0.8	97
139	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1936-1942.	0.8	33
140	Current treatment approaches in follicular lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 740-3.	0.3	3
141	Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. <i>Blood</i> , 2014, 123, 2944-2952.	0.6	505
142	Rituximab Extended Schedule or Re-Treatment Trial for Low-Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402. <i>Journal of Clinical Oncology</i> , 2014, 32, 3096-3102.	0.8	159
143	PI3K Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma. <i>New England Journal of Medicine</i> , 2014, 370, 1008-1018.	13.9	956
144	A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics. <i>Clinical Immunology</i> , 2014, 154, 37-46.	1.4	25

#	ARTICLE	IF	CITATIONS
145	Bulky Aggressive B-Cell Lymphoma: To Radiate or Not to Radiateâ€”That Is the Question. <i>Journal of Clinical Oncology</i> , 2014, 32, 1097-1098.	0.8	4
146	Emerging Therapy for the Treatment of Mantle Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1311-1318.	2.3	5
147	Duvelisib (IPI-145), a PI3K-Î³ Inhibitor, Is Clinically Active in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014, 124, 3334-3334.	0.6	46
148	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2013, 369, 507-516.	13.9	1,449
149	Treatment With The Potent PI3K-Î³ Inhibitor IPI-145 Is Associated With Rapid Decreases In Specific Cytokines, Chemokines and Matrix Metalloproteinases In The Serum Of Patients With Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 1633-1633.	0.6	3
150	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. <i>Blood</i> , 2013, 122, 3060-3060.	0.6	5
151	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. <i>Blood</i> , 2013, 122, 4277-4277.	0.6	3
152	Preliminary Safety and Efficacy Of IPI-145, a Potent Inhibitor Of Phosphoinositide-3-Kinase-Î³, In Patients With Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 677-677.	0.6	20
153	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. <i>Blood</i> , 2012, 120, 304-304.	0.6	18
154	Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2012, 120, 235-235.	0.6	0
155	Is there a role for "watch and wait" in follicular lymphoma in the rituximab era?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 433-8.	0.9	4
156	Bendamustine is effective therapy in patients with rituximabâ€”refractory, indolent Bâ€”cell nonâ€”Hodgkin lymphoma. <i>Cancer</i> , 2010, 116, 106-114.	2.0	217
157	Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy. <i>Clinical Advances in Hematology and Oncology</i> , 2010, 8, 1-16.	0.3	2
158	Frontline therapy in mantle cell lymphoma: The role of high-dose therapy and integration of new agents. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 213-217.	1.2	5
159	The VcR-CVAD Regimen Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma (MCL): First Analysis of E1405 â€” A Phase II Study of VcR-CVAD with Maintenance Rituximab for MCL.. <i>Blood</i> , 2009, 114, 1661-1661.	0.6	9
160	Bendamustine Produces Durable Responses with An Acceptable Long-Term Safety Profile in Patients with Rituximab-Refractory Non-Hodgkin's Lymphoma: A Pooled Analysis.. <i>Blood</i> , 2009, 114, 2681-2681.	0.6	5
161	Expression of the Bcl-2 Family of Regulatory Proteins by Quantitative Immunohistochemistry (AQUA) in Follicular Lymphoma.. <i>Blood</i> , 2009, 114, 4996-4996.	0.6	0
162	Chemotherapy Combinations With Monoclonal Antibodies in Non-Hodgkinâ€™s Lymphoma. <i>Seminars in Hematology</i> , 2008, 45, 90-94.	1.8	32

#	ARTICLE	IF	CITATIONS
163	Marginal Zone Lymphomas: Management of Nodal, Splenic, and MALT NHL. Hematology American Society of Hematology Education Program, 2008, 2008, 359-364.	0.9	40
164	VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network. Blood, 2008, 112, 265-265.	0.6	12
165	Two new indications for rituximab. Clinical Advances in Hematology and Oncology, 2006, 4, 901, 934.	0.3	0
166	Motexafin Gadolinium (MGd) Has Clinical Activity in Relapsed/Refractory Low Grade Lymphomas (LG) and Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).. Blood, 2005, 106, 4758-4758.	0.6	1